Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

Core Viewpoint - Rhythm Pharmaceuticals, Inc. is set to report its fourth quarter and full year 2025 financial results on February 26, 2026, and will provide a corporate update during a live conference call [1] Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases [4] - The company's lead product, IMCIVREE (setmelanotide), is an MC4R agonist approved by the FDA for treating obesity related to specific genetic conditions [4][5] - Setmelanotide is also authorized by the European Commission and the UK's MHRA for similar indications [4][6] Upcoming Events - A live conference call for financial results will take place on February 26, 2026, at 8 a.m. ET, with a recommendation for participants to join ten minutes early [2] - David Meeker, M.D., will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, at 11:10 a.m. ET [2] Webcast Information - Live webcasts of the financial results conference call and the fireside chat will be available on the Rhythm Pharmaceuticals website [3] - Archived webcasts will be accessible for 30 days following the events [3]